Perspective Therapeutics
CATX
52 hedge funds and large institutions have $16M invested in Perspective Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 8 closing their positions.
60% more capital invested
Capital invested by funds: $9.99M → $16M (+$6.01M)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
6% more funds holding
Funds holding: 49 → 52 (+3)
0% more ownership
Funds ownership: 1.3% → 1.3% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$450K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$111K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$52.1K |
| 4 |
PIC
Portland Investment Counsel
Burlington,
Ontario, Canada
|
+$40.1K |
| 5 |
TMWM
Taylor & Morgan Wealth Management
Flint,
Michigan
|
+$14.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$555K |
| 2 |
Jane Street
New York
|
-$37.7K |
| 3 |
HF
HRT Financial
New York
|
-$23.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$21K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$17.8K |
CATX Hedge Fund Activity: Q4 2023 in Review
52 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2023, worth a combined $16M — up 60% from $9.99M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CATX positions and 8 closed out — a net gain of 3 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $450K. The largest seller was Perkins Capital Management, cutting an estimated $555K.
- 52 institutional investors held Perspective Therapeutics (CATX) as of Q4 2023, up from 49 in Q3 2023.
- Funds reported $16M of Perspective Therapeutics stock for Q4 2023, up 60% quarter-over-quarter.
- 11 funds opened new Perspective Therapeutics positions in Q4 2023 and 8 closed out, a net change of +3 holders.
- The largest Perspective Therapeutics buyer in Q4 2023 was Ghost Tree Capital, an estimated $450K added.
- The largest Perspective Therapeutics seller in Q4 2023 was Perkins Capital Management, an estimated $555K sold.
Based on aggregated 13F filings for Q4 2023.